In preparation for the CADTH submission for a manufacturer’s drug Upadacitinib (Rinvoq) for the treatment of psoriatic arthritis (PsA), the Canadian Arthritis Patient Alliance (CAPA) and the Arthritis Society (TAS) developed a survey to hear directly from people living with psoriatic arthritis about their experiences with this condition and any experiences taking Upadacitinib. The survey was shared via e-mails, social media and the CAPA newsletter through our respective Canadian networks and communities. The survey was open from December 15, 2020 until January 11, 2021. We are now pleased to share the submission with our readers here.